Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L M Kelly

Showing results (1-10 of 26) with videos related to

Pageof 3
Sort By:
Natnews|July 1, 1985
Theatre controlB Johnson, L M Kelly
Hospital Topics|August 9, 1980
A county wide disaster drill--team work between two hospitalsL M Kelly, S D Bishop
Issues in Mental Health Nursing|March 12, 2002
The journey of recovery after a rape experienceM E Smith, L M Kelly
Current Drug Targets. Infectious Disorders|May 29, 2003
Immunological approaches for HIV therapyF Lori, L M Kelly, J Lisziewicz
Current Pharmaceutical Design|December 8, 2004
"Virostatics" as a potential new class of HIV drugsL M Kelly, J Lisziewicz, F Lori
Mycopathologia|May 1, 1980
Effect of moderately elevated temperatures on dermatophyte survival in clinical and laboratory-infected specimensJ T Sinski, T M Moore, L M Kelly
The Journal of Antimicrobial Chemotherapy|June 26, 1999
Comparison of agar dilution, microdilution, Etest and disc diffusion to test the activity of trovafloxacin against Pseudomonas aeruginosa, methicillin-resistant Staphylococcus aureus and Streptococcus pneumoniaeL M Kelly, M R Jacobs, P C Appelbaum
Journal of Clinical Microbiology|September 17, 1999
Comparison of agar dilution, microdilution, E-test, and disk diffusion methods for testing activity of cefditoren against Streptococcus pneumoniaeL M Kelly, M R Jacobs, P C Appelbaum
Current Medicinal Chemistry|February 3, 2007
Virostatics: a new class of anti-HIV drugsF Lori, A Foli, L M Kelly, et al.
Blood|July 11, 2000
Insertion of enhanced green fluorescent protein into the lysozyme gene creates mice with green fluorescent granulocytes and macrophagesN Faust, F Varas, L M Kelly, et al.
Pageof 3

Showing results (1-10 of 26) with videos related to

Sort By:
Pageof 3
Natnews|July 1, 1985
Theatre controlB Johnson, L M Kelly
Hospital Topics|August 9, 1980
A county wide disaster drill--team work between two hospitalsL M Kelly, S D Bishop
Issues in Mental Health Nursing|March 12, 2002
The journey of recovery after a rape experienceM E Smith, L M Kelly
Current Drug Targets. Infectious Disorders|May 29, 2003
Immunological approaches for HIV therapyF Lori, L M Kelly, J Lisziewicz
Current Pharmaceutical Design|December 8, 2004
"Virostatics" as a potential new class of HIV drugsL M Kelly, J Lisziewicz, F Lori
Mycopathologia|May 1, 1980
Effect of moderately elevated temperatures on dermatophyte survival in clinical and laboratory-infected specimensJ T Sinski, T M Moore, L M Kelly
The Journal of Antimicrobial Chemotherapy|June 26, 1999
Comparison of agar dilution, microdilution, Etest and disc diffusion to test the activity of trovafloxacin against Pseudomonas aeruginosa, methicillin-resistant Staphylococcus aureus and Streptococcus pneumoniaeL M Kelly, M R Jacobs, P C Appelbaum
Journal of Clinical Microbiology|September 17, 1999
Comparison of agar dilution, microdilution, E-test, and disk diffusion methods for testing activity of cefditoren against Streptococcus pneumoniaeL M Kelly, M R Jacobs, P C Appelbaum
Current Medicinal Chemistry|February 3, 2007
Virostatics: a new class of anti-HIV drugsF Lori, A Foli, L M Kelly, et al.
Blood|July 11, 2000
Insertion of enhanced green fluorescent protein into the lysozyme gene creates mice with green fluorescent granulocytes and macrophagesN Faust, F Varas, L M Kelly, et al.
Pageof 3